Vectibix for Left Sided Metastatic Colorectal Cancer – Details


( Last Updated : April 16, 2018)
Generic Name:
Panitumumab
Project Status:
Complete
Therapeutic Area:
Left Sided Metastatic Colorectal Cancer (mCRC)
Manufacturer:
Amgen Canada Inc.
Brand Name:
Vectibix
Project Line:
Reimbursement Review
Project Number:
PC0118-000
NOC Date:

Details


Strength:
20 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Left Sided Metastatic Colorectal Cancer
Funding Request:
In combination with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS
Review Status:
Complete
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.